Germany’s Added Benefit System May Gain Credibility As It Lauds Zytiga And Cans Trajenta
This article was originally published in The Pink Sheet Daily
Executive Summary
Decisions by Germany’s drug benefit assessor, IQWiG, to recommend novel prostate cancer treatment Zytiga and reject me-too diabetes treatment Trajenta may allay confusion over just how well the country’s new added value assessment process is working